No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
AU Stock MarketDetailed Quotes
ATX Amplia Therapeutics Ltd
- 0.086
- +0.002+2.38%
20min DelayNot Open Dec 24 13:58 AET
33.36MMarket Cap-3.91P/E (Static)
0.087High0.083Low178.59KVolume0.083Open0.084Pre Close15.33KTurnover0.18052wk High0.08%Turnover Ratio387.95MShares0.05552wk Low-0.027EPS TTM19.16MFloat Cap167.493Historical HighLossP/E (Static)222.79MShs Float0.041Historical Low-0.022EPS LYR4.76%Amplitude--Dividend TTM2.61P/B1Lot Size--Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Amplia Therapeutics Ltd: App 4D and Financial Report Half Year ended 30 Sep 2024
Amplia Therapeutics: FDA Granted Fast-Track Designation to Amplia's Lead Drug Narmafotinib in Advanced Pancreatic Cancer >ATX.AU
FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER
Amplia Therapeutics: Advancing Pancreatic Cancer Treatment | ASX:ATX
Amplia Therapeutics Receives Patent for Narmafotinib in Europe, Japan
Amplia Therapeutics Shares Rally 17% on Fourth Confirmed Response in Pancreatic Cancer Trial
Trending AU Stocks
ASX High Dividend ASX High Dividend